Read by QxMD icon Read

Keppra and duration

Sophie Boudriau, Cecilia Hanzel, Julie Massicotte, Laura Sayegh, Jing Wang, Marc Lefebvre
BACKGROUND: Rapidly disintegrating or 'fast-melt' oral formulations have been developed recently to facilitate drug intake among patients. Even though these formulations have helped to improve therapy adherence, some of their limitations include: the dissolution time, their facility to be swallowed, and the dosage strengths that may be accommodated. To overcome these limitations, a novel, porous, quickly disintegrating, and easier-to-swallow fast-melt formulation based on powder-liquid, three-dimensional printing (3DP) technology has been developed...
June 2016: Drugs in R&D
Vivek Ramakrishnan, Robert Dahlin, Omid Hariri, Syed A Quadri, Saman Farr, Dan Miulli, Javed Siddiqi
BACKGROUND: Seizures account for significant morbidity and mortality early in the course of traumatic brain injury (TBI). Although there is sufficient literature suggesting short-term benefits of antiepileptic drugs (AEDs) in post-TBI patients, there has been no study to suggest a time frame for continuing AEDs in patients who have undergone a decompressive craniectomy for more severe TBI. We examined trends in a level-II trauma center in southern California that may provide guidelines for AED treatment in craniectomy patients...
2015: Surgical Neurology International
Roy G Beran, Paul J Spira
INTRODUCTION: Chronic daily headache (CDH) represents a temporal profile of headache (15+ days/month; 4+ hours/day; >6 months). We report the first comprehensive and largest levetiracetam (LEV) trial in CDH. METHODS: A 27-week, multi-centre, randomised, placebo-controlled, cross-over, phase III B study assessed efficacy of a target of 3 g/day LEV of 6 placebo tablets/day in CDH. Primary efficacy was headache-free rate (HFR) while secondary parameters were loss of diagnostic criteria; severity; duration; disability; associated features; pain; and quality of life...
April 2011: Cephalalgia: An International Journal of Headache
I G Rudakova, A S Kotov, S V Kotov, Iu A Belova, N S Lavrent'eva
One hundred and thirty-eight patients (76 women and 62 men, aged from 16 to 65 years) with symptomatic partial epilepsy (n=128) and idiopathic generalized epilepsy (n=10) have been studied. All patients received keppra on regiments of monotherapy (n=30) and polytherapy (n=108). The study included evaluation of anamnesis, clinical and neurophysiological examination, routine EEG and/or video-EEG-monitoring, MRI of the brain, assessment of effectiveness, tolerability and quality of life (QUALIE-31, version 1)...
2009: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
Alain Matagne, Doru-Georg Margineanu, Heidrun Potschka, Wolfgang Löscher, Philippe Michel, Benoit Kenda, Henrik Klitgaard
Seletracetam is a pyrrolidone derivative with a one-log-unit higher affinity for the synaptic vesicle protein 2A (SV2A) than levetiracetam (Keppra). This study explored its anticonvulsant properties in animal models of epilepsy. Seletracetam reduced both the amplitude and repetitive firing of population spikes induced by a high K(+)/low Ca(2+) concentration fluid (HKLCF) in rat hippocampal slices. The reduction of HKLCF-induced increases in population spike amplitude was particularly pronounced, and occurred at approximately 10 times lower seletracetam concentrations than previously observed for levetiracetam...
July 1, 2009: European Journal of Pharmacology
Giuseppina Martella, Paola Bonsi, Giuseppe Sciamanna, Paola Platania, Graziella Madeo, Annalisa Tassone, Dario Cuomo, Antonio Pisani
PURPOSE: We analyzed the effects of seletracetam (ucb 44212; SEL), a new antiepileptic drug candidate, in an in vitro model of epileptic activity. The activity of SEL was compared to the effects of levetiracetam (LEV; Keppra), in the same assays. METHODS: Combined electrophysiologic and microfluorometric recordings were performed from layer V pyramidal neurons in rat cortical slices to study the effects of SEL on the paroxysmal depolarization shifts (PDSs), and the simultaneous elevations of intracellular Ca(2+) concentration [Ca(2+)](i)...
April 2009: Epilepsia
Eitan Auriel, Vladimir Chistik, Ilan Blatt, Nahum Margolin, Miri Neufeld
BACKGROUND: Levetiracetam (LEV) is a new generation anti-epileptic drug, which has been approved as add-on therapy for partial epilepsy. The mechanism of LEV is not yet completely understood. AIM: To evaluate the efficacy and tolerability of LEV in adult patients with refractory epilepsy. METHODS: We report the results of 49 patients with refractory epilepsy, with partial and generalized seizures, who received LEV as an add-on treatment, in two tertiary medical centers...
April 2007: Harefuah
G Steve Miller
BACKGROUND: Headache is a frequent occurrence among children and adolescents. Chronic headaches can be severe and disabling, and require prophylactic treatment; however, additional data on the use of prophylactic medications for migraine in children are needed. OBJECTIVE: To review the efficacy and safety of levetiracetam (Keppra) in pediatric patients with a history of recurrent headache. DESIGN/METHODS: Data from 19 pediatric patients were retrospectively reviewed...
March 2004: Headache
Michael Madeja, Doru Georg Margineanu, Ali Gorji, Elke Siep, Paul Boerrigter, Henrik Klitgaard, Erwin-Josef Speckmann
Levetiracetam (ucb L059; Keppra) is a novel antiepileptic drug. Its effects on action potential generation and voltage-operated potassium currents were studied in acutely isolated hippocampal CA1 neurones from rat and guinea pig, using the patch-clamp technique in the whole-cell configuration. (i) Levetiracetam reduced repetitive action potential generation and affected the single action potential. Levetiracetam, 100 microM, decreased the total number of action potentials and reduced the total depolarisation area of repetitive action potentials by 21%...
October 2003: Neuropharmacology
Elinor Ben-Menachem, Pascal Edrich, Betty Van Vleymen, Josemir W A S Sander, Bernd Schmidt
PURPOSE: To evaluate the long-term clinical usefulness of levetiracetam (LEV, Keppra((R))(1)) as add-on therapy in patients with refractory epilepsy. METHODS: Data for all 1422 patients with refractory epilepsy treated with LEV during the development program were analyzed for changes in seizure frequency per week, seizure freedom, and adverse events. RESULTS: Median percent reduction from baseline in seizure frequency per week over the whole treatment period was 39...
February 2003: Epilepsy Research
J French, P Edrich, J A Cramer
PURPOSE: This report provides detailed review of safety information on levetiracetam (LEV) (Keppra), a new antiepileptic drug. METHODS: The integrated summary of safety report submitted for regulatory review was examined to collate information about abnormal laboratory tests values and adverse event reports collected during the overall LEV development program. Analyses included 3347 patients exposed to LEV in clinical trials for epilepsy, cognition, and anxiety disorders...
November 2001: Epilepsy Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"